Biopharma Launch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Barcelona, Spain - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines, has started marketing XEMBIFY®, its 20% subcutaneous immunoglobulin, in Spain. This plasma medicine is indicated for treating primary immunodeficiencie...

June 26, 2023 Grifols begins European launch of XEMBIFY® in Spain to treat immunodeficiencies Print this news Download the press release Primary immunodeficiencies (PID) affect...